Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
06:32pm, Tuesday, 06'th Aug 2024
Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.40 per share a year ago.
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
04:01pm, Tuesday, 06'th Aug 2024
Second quarter total revenue of $36.8 million, which includes TAVALISSE® net product sales of $26.4 million, REZLIDHIA® net product sales of $5.2 million and GAVRETO® net product sales of $1.9 mill
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Tuesday, 30'th Jul 2024
Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
08:05am, Tuesday, 30'th Jul 2024
SOUTH SAN FRANCISCO, Calif. , July 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2024 financial results after market close
Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
03:06am, Wednesday, 24'th Jul 2024
Rigel Pharmaceuticals focuses on innovative therapeutics for hematological conditions and cancers, with FDA-approved products Tavalisse, Rezlidhia, and Gavreto targeting specific diseases. RIGL's pipe
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05am, Friday, 12'th Jul 2024
SOUTH SAN FRANCISCO, Calif. , July 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approve
Rigel Announces Reverse Stock Split
08:00am, Tuesday, 25'th Jun 2024
SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares o
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
04:05pm, Monday, 24'th Jun 2024
GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announce
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
09:36am, Monday, 17'th Jun 2024
Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit.
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
03:05am, Friday, 14'th Jun 2024
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML , including
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
08:13am, Monday, 03'rd Jun 2024
- Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetocl
Rigel to Present at the Jefferies Global Healthcare Conference
08:05am, Thursday, 30'th May 2024
SOUTH SAN FRANCISCO, Calif. , May 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overv
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
05:00pm, Thursday, 23'rd May 2024
Oral presentation of f inal five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients, including t
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 10'th May 2024
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript
09:46pm, Tuesday, 07'th May 2024
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Ra
